Back to Search Start Over

A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers

Authors :
Carolin Vegvari
Christoforos Hadjichrysanthou
Frank de Wolf
Roy M. Anderson
Alison Ower
Emma Lawrence
Source :
Journal of Alzheimer's Disease
Publication Year :
2017
Publisher :
IOS Press, 2017.

Abstract

Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease, with no effective treatment or cure. A gold standard therapy would be treatment to slow or halt disease progression; however, knowledge of causation in the early stages of AD is very limited. In order to determine effective endpoints for possible therapies, a number of quantitative surrogate markers of disease progression have been suggested, including biochemical and imaging biomarkers. The dynamics of these various surrogate markers over time, particularly in relation to disease development, are, however, not well characterized. We reviewed the literature for studies that measured cerebrospinal fluid or plasma amyloid-β and tau, or took magnetic resonance image or fluorodeoxyglucose/Pittsburgh compound B-positron electron tomography scans, in longitudinal cohort studies. We summarized the properties of the major cohort studies in various countries, commonly used diagnosis methods and study designs. We have concluded that additional studies with repeat measures over time in a representative population cohort are needed to address the gap in knowledge of AD progression. Based on our analysis, we suggest directions in which research could move in order to advance our understanding of this complex disease, including repeat biomarker measurements, standardization and increased sample sizes.

Details

ISSN :
18758908 and 13872877
Volume :
59
Database :
OpenAIRE
Journal :
Journal of Alzheimer's Disease
Accession number :
edsair.doi.dedup.....b0eed503acaa0b8c8fcb6d73e1f3f757
Full Text :
https://doi.org/10.3233/jad-170261